OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.

Area of Science:

• Immunology
• Molecular Biology
• Cancer Immunotherapy

Background:

• OX40 (tumor necrosis factor receptor superfamily) is a costimulatory molecule expressed on T cells.
• OX40 agonists are investigated for cancer immunotherapy, with a proposed mechanism involving impaired regulatory T cell (Treg) function.
• Previous studies suggested OX40 agonism could reduce Treg suppressive capacity.

Purpose of the Study:

• To directly evaluate the effect of OX40 agonism on Treg function using updated methodologies.
• To clarify the mechanistic impact of OX40 agonists on T cell subsets in the context of antitumor immunity.

Main Methods:

• Utilized advanced tools to assess the direct impact of OX40 agonist antibodies on Treg function in a murine model.
• Analyzed cytokine production, cell proliferation, and suppressive capacity of Tregs and conventional T cells (Tconvs) upon OX40 stimulation.

Main Results:

• OX40 agonist antibodies do not intrinsically impair Treg suppressive function.
• Enhanced IL-2 production by conventional CD4 T cells (Tconvs) was observed, leading to increased proliferation of both Tregs and Tconvs.
• OX40-stimulated Tregs maintained their suppressive function and additionally expressed IFN-γ, TNF-α, and granzyme B.

Conclusions:

• OX40 agonism does not diminish Treg function; instead, it boosts T cell responses and Treg proliferation.
• These findings resolve mechanistic questions about OX40 agonist immunotherapy.
• Data supports the development of combination therapies targeting distinct T cell functions for enhanced antitumor immunity.